Multicenter Safety Trial Assessing an Innovative Tumor Molecular and Cellular Print Medical Device in Glioma

Inclusion Criteria: * more or equal than 18 years old * patient affiliated to social security or similarly regime * informed consent form signed * glial tumor suspicion * Stereotaxic biopsy indication * Karnofsky score \> 70% * Hematological assessment : * neutrophils \> 1500/mm3 * Platelet \> 150 000 * blood Creatinin normal * alkaline Phosphatases and transaminases no more than two times normal * Bilirubin \< 1.5 times normal Exclusion Criteria: * Pregnant women and lactating mothers * Ward of court or under guardianship * Adult unable to express their consent * Person deprived of freedom by judicial or administrative decision * Person hospitalized without their consent * Person under legal protection * Person participating in another clinical study * Intratumoral hemorrhage MRI detected * Treatment anticoagulant or antisludge treatments * Active Infections and non controled or medical affection or psychiatric intercurrent non treated * Evolutive cerebral oedema without corticoid response * Non controled Epilepsy without antiepileptics response * Susceptibility to Medical Device materials allergy